5-Azacitidine SC/IV 75 mg/m² days 1-7 q28d — r/r AITL (epigenetic-targeted)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Components | DRUG-AZACITIDINE |
|---|
| ID | REG-AZACITIDINE-AITL |
|---|---|
| Type | Regimen |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-ESMO-PTCL-2024 SRC-NCCN-BCELL-2025 |
Notes
RUYUAN-2 / Lemonnier 2018-2023: emerging epigenetic therapy specifically active in AITL — ORR 50-75% in r/r AITL (small series). Mechanistic rationale: AITL has high frequency of TET2, IDH2, DNMT3A mutations (clonal hematopoiesis-like) creating epigenetic dysregulation that hypomethylating agents exploit. Off-label use; OFF-FDA but mentioned in NCCN PTCL-NOS with TFH features. Slow-onset response — minimum 4-6 cycles before declaring failure. Particularly attractive in AITL where conventional options are dismal AND drug already on shelf in heme practice (vs belinostat / romidepsin / pralatrexate not registered in UA).
Used By
Indication
IND-AITL-2L-AZACITIDINE- IND-AITL-2L-AZACITIDINE